Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1215/03616878-29-4-5-925 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hospital outbreak of NDM-producing Klebsiella pneumoniae in a surgical intensive care unit: sink traps as the causing source of epidemic strain resurgence.
Am J Infect Control
January 2025
Hygiene Department, Nantes University Hospital, Nantes, France.
We report the management of a New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae outbreak in a surgical intensive care unit over 1 year. NDM-producing Enterobacterales were isolated from sink traps. The installation of new sink traps closed the outbreak.
View Article and Find Full Text PDFContagion comeback: unravelling the measles outbreak across the USA.
Front Public Health
January 2025
Atish Dipankar University of Science and Technology, Dhaka, Bangladesh.
Measles, a highly contagious respiratory illness caused by the measles virus (MeV), poses significant global and national public health challenges despite advancements in vaccination efforts. Though measles was declared eliminated in the United States in 2000, recent years have seen a resurgence of cases, particularly in under-vaccinated communities. This resurgence is compounded by factors such as vaccine hesitancy, the impact of the COVID-19 pandemic on immunization rates, and international travel introducing new cases from endemic regions.
View Article and Find Full Text PDFA Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments.
Appl Biosaf
December 2024
Advarra, Columbia, Maryland, USA.
Introduction: Discussion of gene-modified investigational products (IPs) in clinical trials has largely focused on nucleic acid-based vectors, viral vectors, and gene-modified cellular products involving mammalian cells. Use of bacteria and bacteriophages as IPs is resurgent, and discussion of the risks associated with genetic modification of these organisms has become pertinent to the biosafety community.
Methods: This review article summarizes the United States Food and Drug Administration classification for IPs comprising bacteria or bacteriophages and provides an overview of clinical trials conducted to date involving genetically modified bacteria.
A sequential study of Chikungunya fever cases notified in the urban setup of India.
J Family Med Prim Care
November 2024
Department of Community Medicine, Government Medical College, Surat, Gujarat, India.
Context: Chikungunya's resurgence highlights reporting and awareness challenges.
Aims: To analyze trends in 170 laboratory-confirmed Chikungunya cases in Urban Surat's Central Sentinel Surveillance (2016-2020), supplemented by a subset (n = 30) examining perceptions, attitudes, and risk reduction practices based on notification level.
Results: Notification rates peaked in 2017 (1.
Antimicrobial peptide LL37 is potent against non-growing cells despite a slower action rate.
mSphere
December 2024
Department of Physics and Astronomy, California State University, Northridge, California, USA.
Unlabelled: Antimicrobial peptides (AMPs) have long been considered as potential agents against non-growing, dormant cells due to their membrane-targeted action, which is largely independent of the cell's growth state. However, the relationship between the action of AMPs and the physiological state of their target cells has been unclear, with recent reports offering conflicting views on the efficacy of AMPs against bacteria in a stationary phase. In this study, we employ single-cell approaches combined with population-level experiments to examine the action of human LL37 peptides against cells in different growth phases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!